

NEWS RELEASE, 06 SEPTEMBER 2018

EVOTEC AG LISTED IN MDAX

▶ DUAL-LISTING OF EVOTEC AG SHARE IN TECDAX AND MDAX AS OF 24 SEPTEMBER 2018

Hamburg, Germany, 06 September 2018:


Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its shares will be included in the MDAX as of 24 September 2018 as announced by Deutsche Börse on 05 September 2018.

This dual listing of the Evotec shares in both TecDAX and MDAX results from the rule changes regarding the inclusion of companies in the MDAX, SDAX and TecDAX. As a consequence of this rule change, the tech and classic sectoral separation in the indices will be eliminated and tech companies may also be included in the MDAX and SDAX going forward. The MDAX consists of the 60 largest and most-traded companies in Germany. Evotec was able to meet the relevant criteria of the MDAX index regarding market capitalisation of the free float as well as trading volume.

Further information on the rule changes by Deutsche Börse can be found in the Guide Equity Indices (valid from 31.08.2018) which can be found online at https://www.dax-indices.com/resources.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including, Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.



FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.